

CANbridge, Azaya do cancer drug R&D in China, North Asia

12 September 2013 | News | By BioSpectrum Bureau



Singapore: CANbridge Life Sciences entered into a deal with US-based Azaya Therapeutics, to develop and commercialize the latter's investigational drug, ATI-1123

CANbridge, which is a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, will use the drug for treatment of non-small cell lung cancer (NSCLC), and potentially other solid tumor cancer indications, in China and North Asia.

ATI-1123, a liposomal formulation of docetaxel, has completed a FDA-approved phase I trial in 29 patients with solid tumor cancers who had failed on other therapies. Phase II trials in the US are planned in non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and soft-tissue sarcoma.